The Lancet Haematology/X
Jun 13, 2025, 23:21
Paul J Bröckelmann Shares The Lancet Haematology Commission Update on Adverse Events at EHA 2025
The Lancet Haematology shared a post on X:
“Today at EHA2025 Dr Paul J Bröckelmann shared insights from The Lancet Haematology Commission on Adverse Events.
Our 2025 Series updates priority areas on measuring and managing toxicities in new haematology treatment.”
Paul J Bröckelmann presented updates from The Lancet Haematology Commission’s 2025 Series at EHA 2025, focusing on improving how adverse events are measured and managed in modern haematology therapies.
You Can Find More Posts on Hemostasis Today.
-
Nov 30, 2025, 13:23Ditte Vestergaard Hansen and Colleagues on Predictors of VTE Post-Stroke
-
Nov 30, 2025, 13:10Divyaswathi Citla Sridhar and Team Report Higher VTE Rates in Obese Users of Certain Estrogen-Progestin Combinations
-
Nov 30, 2025, 12:40Timos Papagatsias: Interested in Social Media in the Hematology Space?
-
Nov 30, 2025, 12:15Raphaël Liévin: In March 2026 SFH Will Host Its Very First Young EHA Research Meeting (YERM)!
-
Nov 30, 2025, 11:51Mohamed Aly Saad Aly on Microcatheters for Superselective Arterial Embolization
-
Nov 29, 2025, 18:55Ahmad Thuaimer: Success Story – Advanced Interventional Care for DVT
-
Nov 29, 2025, 17:37Almahdi Ali Explores Ipsilateral Paradoxical Thromboembolism at 22nd European Angiology Days 2025
-
Nov 29, 2025, 17:23Jack Shuang Hou Shares Major Neurology Updates This Week
-
Nov 29, 2025, 16:52Federica Fogacci on Further Strengthening Collaboration Within the Lp(a)CCELERATE Study